ASTEROID Trial

Effect of High-intensity Rosuvastatin therapy on Regression of Coronary Atherosclerosis

Objective

To investigate the effects of high intensity rosuvastatin therapy on coronary atherosclerosis.

Patient Population

N=471; patients with coronary artery disease (?1 lesion in a native coronary artery>20% stenosed) and those who have not received statin therapy for >3 years within 12 months of screening)

Study Design

Patients received rosuvastatin 40 mg for 24 months.

Results

The changes in atherosclerotic plaque was as follows:

Overall, percent atheroma volume regression was observed in 64% of patients and nominal total atheroma volume regression was observed in 78% of patients.
LDL-C reduced by 53%, HDL-C increased by 15% and approximately 75% patients achieved LDL-C goal of <70 md/dL.
Rosuvastatin 40 mg was well tolerated, with 4% patients reported musculoskeletal complaints and <1% experienced elevated liver enzymes or creatinine kinase.

Conclusion

Rosuvastatin 40 mg therapy over 24 months was associated with regression of atherosclerotic plaques and was well tolerated.

Am J Cardiol 2009; 104: 29-35